Literature DB >> 7041307

Behçet's disease.

J B Michelson, F V Chisari.   

Abstract

Behçet's disease is characterized by three primary components: iridocyclitis (historically with hypopyon), aphthous lesions in the mouth, and ulceration of the genitalia. Erythema nodosum, arthropathy and thrombophlebitis often accompany these manifestations, but the ocular symptoms may be the most important and serious manifestations of the disease. Central nervous system involvement, most often due to necrotizing vasculitis, may be the most protean manifestation of the disease, leading to death. The frequency of ocular manifestations is 70-85% in patients with the disease; the underlying disease mechanism in all organ systems is an occlusive vasculitis. Although the most common ocular symptom is that of anterior uveitis, often with hypopyon as a very late sign, the presence of necrotizing retinal vascular lesions is well known and often obscured by the severity of the anterior reaction. Definitions, incidence, clinical characteristics, differential diagnosis, and management of Behçet's ocular disease are discussed, as are the interrelationships of the different organ manifestations. The ophthalmologist should be familiar with the full spectrum of disease presentation since he or she may be the first physician to encounter the Behçet's patient.

Entities:  

Mesh:

Year:  1982        PMID: 7041307     DOI: 10.1016/0039-6257(82)90079-0

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  24 in total

1.  Behçet's disease: activated T lymphocytes in retinal perivasculitis.

Authors:  D G Charteris; C Champ; A R Rosenthal; S L Lightman
Journal:  Br J Ophthalmol       Date:  1992-08       Impact factor: 4.638

2.  Anterior uveitis and hypopyon.

Authors:  L P D'Alessandro; D J Forster; N A Rao
Journal:  Trans Am Ophthalmol Soc       Date:  1991

Review 3.  Retinal vasculitis.

Authors:  M D Sanders; E M Graham
Journal:  Postgrad Med J       Date:  1988-07       Impact factor: 2.401

4.  Effective Ankaferd Hemostat Treatment For Severe Intractable Chronic Deep Leg Ulcer Associated With Behçet's Disease.

Authors:  Rafiye Çiftçiler; Erdinç Çiftçiler; İbrahim Haznedaroğlu
Journal:  Arch Rheumatol       Date:  2019-04-26       Impact factor: 1.472

5.  Pacemaker implantation in a patient with a Behçet's disease associated with superior vena cava obstruction.

Authors:  I Or; N Roguin; M Yahalom; V Birjiniuk; S Amikam
Journal:  Cardiovasc Intervent Radiol       Date:  1986       Impact factor: 2.740

6.  Plasma exchange in the therapy of Behçet's disease.

Authors:  M B Raizman; C S Foster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

7.  Treatment and visual prognosis in Behçet's disease.

Authors:  D Benezra; E Cohen
Journal:  Br J Ophthalmol       Date:  1986-08       Impact factor: 4.638

8.  Evaluation of the International Study Group for Behçet's Disease Criteria in Brazilian patients.

Authors:  R E Heyman; M B Ferraz; C R Gonçalves; E Atra
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

9.  Behçet's syndrome: treatment with chlorambucil.

Authors:  J H Elliott; W H Ballinger
Journal:  Trans Am Ophthalmol Soc       Date:  1984

10.  Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity.

Authors:  R Oktay Kaçmaz; John H Kempen; Craig Newcomb; Sapna Gangaputra; Ebenezer Daniel; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; C Stephen Foster
Journal:  Am J Ophthalmol       Date:  2008-08-16       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.